乳山市两所医院鲍曼不动杆菌耐药性及流行性分析

目的分析乳山市两所医院鲍曼不动杆菌的耐药性及流行特点。方法收集乳山市人民医院、乳山市中医院2015年1-12月临床分离鲍曼不动杆菌,进行药敏试验,选取50株鲍曼不动杆菌采用脉冲场凝胶电泳分析菌株同源性。结果共收集鲍曼不动杆菌158株,其中乳山市人民医院108株,乳山市中医院50株。标本来源以痰液(59.9%)为主,分布科室以呼吸科(39.8%)和ICU(25.3%)为主。药敏结果显示,所检测菌株对氨曲南、氨苄西林、头孢西丁100.0%耐药,对多黏菌素B、替加环素均敏感。50株鲍曼不动杆菌可分为A~E共5种型别,其中A型又分为A1、A2、A3等3个亚型,为主要流行型别。结论乳山市两所医院鲍曼不动杆菌耐药问题较严峻,主要存在于呼吸科、ICU等科室,以引起呼吸道感染为主,在两所医院不同科室间存在播散流行。     

抗菌药物临床应用管理办法

第一章 总则 第一条为加强医疗机构抗菌药物临床应用管理，规范抗菌药物临床应用行为，提高抗菌药物临床应用水平，促进临床合理应用抗菌药物，控制细菌耐药，保障医疗质量和医疗安全，根据相关卫生法律法规，制定本办法。     

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

BackgroundAlthough the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in non–small-cell lung cancer (NSCLC) patients with tumors harboring activating mutations of EGFR, most subsequently develop acquired resistance. One recognized resistance mechanism occurs through activation of bypass signaling via the hepatocyte growth factor (HGF)-MET pathway. INC-280 is a small molecule kinase inhibitor of MET. We sought to demonstrate the activity of INC-280 on select NSCLC cell lines both as a single agent and in combination with erlotinib using exogenous HGF to simulate MET up-regulation.MethodsFour NSCLC cell lines (HCC827, PC9, H1666, and H358) were treated with either single-agent INC-280 or in combination with erlotinib with or without HGF. The activity of the drug treatments was measured by cell viability assays. Immunoblotting was used to monitor expression of EGFR/pEGFR, MET/pMET, GAB1/pGAB1, AKT/pAKT, and ERK/pERK as well as markers of apoptosis (PARP and capase-3 cleavage) in H1666, HCC827, and PC9.ResultsAs a single agent, INC-280 showed minimal cytotoxicity despite potent inhibition of MET kinase activity at concentrations as low as 10 nM. Addition of HGF prevented erlotinib-induced cell death. The addition of INC280 to HGF-mediated erlotinib-resistant models restored erlotinib sensitivity for all cell lines tested, associated with cleavage of both PARP and caspase-3. In these models, INC-280 treatment was sufficient to restore erlotinib-induced inhibition of MET, GAB1, AKT, and ERK in the presence of HGF.ConclusionAlthough the MET inhibitor INC-280 alone had no discernible effect on cell growth, it was able to restore sensitivity to erlotinib and promote apoptosis in NSCLC models rendered erlotinib resistant by HGF. These data provide a preclinical rationale for an ongoing phase 1 clinical trial of erlotinib plus INC-280 in EGFR-mutated NSCLC.     

Mentha spicata as natural analgesia for treatment of pain in osteoarthritis patients

Osteoarthritis, as the major cause of chronic musculoskeletal pain, impacts people aged 45 and above. The first line analgesic treatments have reported minimal short term effects. The use of essential oils as pain killer has increased, recently. Mentha spicata, or spearmint essential oil is famous due to its anti-flatulence effects, but one less known biological activity of spearmint is its analgesic activity. The aim of our study was to confirm the analgesic effects of M. spicata essential oil. In this review, we evaluated the articles on analgesic activities of M. spicata essential oil from different relevant databases (PubMed, Science Direct, Wiley, Taylor & Francis, and Springer) without limitation up to April 30, 2016. Different animal studies have reported the analgesic effects of M. spicata essential oil and its main abundant compounds such as carvone, limonene and menthol, also, the efficacy and safety of spearmint oil in reducing of pain severity were confirmed in osteoarthritis patients. In spite of the beneficial effects of spearmint oil in reducing of pain, other large clinical trials are required to confirm the efficacy and safety of M. spicata oil.     

银离子愈邦敷料联合银锌霜治疗重症剥脱性药疹疗效评价

目的:评价新型敷料银离子愈邦联合银锌霜应用于重症药疹大面积剥脱性创面愈合的疗效。方法:42例患者随机分为观察组与对照组,每组各21例。观察组采用愈邦与银锌霜,对照组采用油纱与金霉素眼膏。观察创面愈合时间、患者疼痛度,换药次数。结果:观察组创面愈合时间平均10.10±2.88天,对照组平均13.44+3.16天,差异有极显著统计学意义(P0.01)。观察组换药时疼痛总VAS评分为2.73+1.15分,对照组3.58+2.11分,差异有极显著统计学意义(P0.01);观察组换药次数平均2.47±1.15次,对照组平均4.45±1.22次,差异有极显著统计学意义(P0.01)。结论:愈邦敷料用于重症药疹大面积剥脱性皮损换药疗效肯定。